Caris Life designates Virginia Cancer...
Home  »  Community News  »  Caris Life designate...
May
28
ragupathyrenganathan
Caris Life designates Virginia Cancer Specialists as Caris Center of Excellence – Courtesy (Pharmabiz)
Pharma News
0
, ,

Irving, Texas
Wednesday, May 27, 2015, 12:00 Hrs  [IST]

Caris Life Sciences announced the designation of Virginia Cancer Specialists (VCS), a leading oncology practice in Virginia serving thousands of cancer patients each year and member of the US Oncology Network, as a center of excellence site in the Caris Centers of Excellence for Precision Medicine Network (Network).

“As the largest community-based practice in the northern Virginia metropolitan region, the physicians at Virginia Cancer Specialists bring real-world perspectives for integrating the delivery of personalized medicine in large volume clinical settings,” said Dr. John Marshall, chairman of the Network, Professor of Medicine and Oncology at Georgetown University School of Medicine and Chief of Hematology/Oncology at Georgetown Lombardi Comprehensive Cancer Center. “I am excited to welcome Virginia Cancer Specialists to the Network and pleased that the Caris Centers of Excellence for Precision Medicine Network now consists of academic centers, health systems and community-based practices to holistically develop standardized tumour profiling guidelines.”

As a Network member, Virginia Cancer Specialists will actively participate in the development of standards of care and best practices for integrating molecular profiling in oncology practice, while also striving to increase widespread adoption and patient access to personalized medicine in clinical settings. Virginia Cancer Specialists will also leverage Caris’ multiple-technology tumour profiling service, Caris Molecular Intelligence, to enable the practice of precision medicine by identifying therapy options and clinical trial opportunities based on the unique characteristics of a patient’s tumour.

“The multiple technology approach to interrogate a tumour’s DNA, RNA and protein expression provided by Caris, equips our physicians with more actionable and up-to-date molecular data to inform therapy selection and enhance clinical trial participation,” said Alexander Spira, M.D., Ph.D., FACP, Co-Director of the VCS Research Institute at Virginia Cancer Specialists. “We are excited to join the Caris Network effort and work with other leading institutions to further shape routine use tumour profiling and enhance the delivery of precision medicine for patients.”

Caris Molecular Intelligence, a service that correlates molecular data from a tumour with biomarker and drug associations from the latest clinical and scientific cancer literature, is the key technology platform used across the Network to enable the delivery of precision medicine.  This information is used to help inform treatment decisions by identifying therapies that have the potential to be most effective and to rule out those that are less likely to work, based on the unique molecular characteristics of an individual patient’s cancer. The Caris Molecular Intelligence system uses multiple technology platforms combined with sophisticated bioinformatics to develop clinically actionable reports for more than 70,000 patients to date.

Caris Life Sciences is a leading biotechnology company focused on fulfilling the promise of precision medicine through quality and innovation.

For the past 40 years, Virginia Cancer Specialists (VCS) has contributed to the campaign against cancer and diseases of the blood. With nine state-of-the-art locations throughout Northern Virginia, VCS is on the cutting-edge of providing patients access to the latest technology, physician collaboration, clinical research, and the most advanced cancer treatments.



Leave a reply

You must be logged in to post a comment.